Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP310982.RAXrsdK4Vftnn1hfuttkGtAQ1VE0xgEcqGxM5WWZ6xBig130_assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP310982.RAXrsdK4Vftnn1hfuttkGtAQ1VE0xgEcqGxM5WWZ6xBig130_provenance.
• NP628422.RAqEf_Wm_lUPaZg2KAt57Fqj9WdY1DtO7Ig_RckA7T8CQ130_assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP628422.RAqEf_Wm_lUPaZg2KAt57Fqj9WdY1DtO7Ig_RckA7T8CQ130_provenance.
• NP495932.RATaDp-Ylfos1Xgy0zljtuz1mWLEUe_PeunpzjH_TN6Zs130_assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP495932.RATaDp-Ylfos1Xgy0zljtuz1mWLEUe_PeunpzjH_TN6Zs130_provenance.
• assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP386094.RAEuIpuTrkWqWD55yLohml9QyBOTZ6JccfzzEOd_yKVzo130_assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP386094.RAEuIpuTrkWqWD55yLohml9QyBOTZ6JccfzzEOd_yKVzo130_provenance.
• NP322449.RAUM0PUjmddMo5H5z5SKGu3Jzr1fnpXu6qFXq3fQxJOd4130_assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP322449.RAUM0PUjmddMo5H5z5SKGu3Jzr1fnpXu6qFXq3fQxJOd4130_provenance.
• NP775155.RAXyDUs-QdNAHNzgdMFl8PcjtMqzmErW4qNELlwOThOHg130_assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP775155.RAXyDUs-QdNAHNzgdMFl8PcjtMqzmErW4qNELlwOThOHg130_provenance.
• assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP775066.RAhX-zb-2xFtcxD4uq0JaF-lJ-l2kiUEetWkIpiw7f0jM130_assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP775066.RAhX-zb-2xFtcxD4uq0JaF-lJ-l2kiUEetWkIpiw7f0jM130_provenance.
• NP775145.RAuIDI8uYUEis_-6TcCWUpxqpY_LtaqGICL8aY1c4P22M130_assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP775145.RAuIDI8uYUEis_-6TcCWUpxqpY_LtaqGICL8aY1c4P22M130_provenance.
• NP847913.RACjRo9a7Frmeg80w9mP_Ge5QBZmN6BQMqJ1cjo9Hf-rg130_assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP847913.RACjRo9a7Frmeg80w9mP_Ge5QBZmN6BQMqJ1cjo9Hf-rg130_provenance.
• NP847918.RAAZ58JZ5_7tDl97MmsxDU0r6sXA60FFg8NKWKmo1bchM130_assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP847918.RAAZ58JZ5_7tDl97MmsxDU0r6sXA60FFg8NKWKmo1bchM130_provenance.
• NP362384.RAl6L4AYkgchLQXC9hjI_iaXC7jeT9n5aZRodndJki01k130_assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP362384.RAl6L4AYkgchLQXC9hjI_iaXC7jeT9n5aZRodndJki01k130_provenance.
• NP847908.RAetKs_qwi5KJo_uOxmxbhkuRpyzGT5x5-KpP8o8YEwNU130_assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP847908.RAetKs_qwi5KJo_uOxmxbhkuRpyzGT5x5-KpP8o8YEwNU130_provenance.
• NP847910.RAaSLFMLyhyQddH2DFORh97llms_XIhRBTtog1VV0qVFU130_assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP847910.RAaSLFMLyhyQddH2DFORh97llms_XIhRBTtog1VV0qVFU130_provenance.
• NP847916.RAXAmIEu3VEpfVkAHI4nPlaFvYuk-QRy28a078dH_9y98130_assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP847916.RAXAmIEu3VEpfVkAHI4nPlaFvYuk-QRy28a078dH_9y98130_provenance.
• NP847917.RAefb1iegvyu2U29CQcStg0zorfPubHdeGjHmZk87fzNs130_assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP847917.RAefb1iegvyu2U29CQcStg0zorfPubHdeGjHmZk87fzNs130_provenance.
• NP799350.RAv7L7RwZG4WRLmoHDFpc4oODtgSHPgxfi2OkYt9LoKxg130_assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP799350.RAv7L7RwZG4WRLmoHDFpc4oODtgSHPgxfi2OkYt9LoKxg130_provenance.
• NP223338.RA4o-J3ki0ch8viUIBlDr6TTLmoUAwU7cufp5HrX73DmM130_assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP223338.RA4o-J3ki0ch8viUIBlDr6TTLmoUAwU7cufp5HrX73DmM130_provenance.
• NP322432.RA92jb1p57Ltjsq4VYgIjMxThw1KPwaQJD611MpHomK5o130_assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP322432.RA92jb1p57Ltjsq4VYgIjMxThw1KPwaQJD611MpHomK5o130_provenance.
• NP223352.RAOLZrhSbYx1F4gRh6ApYS3ZYh1g2iPHsYujuS5fpVHaE130_assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP223352.RAOLZrhSbYx1F4gRh6ApYS3ZYh1g2iPHsYujuS5fpVHaE130_provenance.
• NP362376.RA5S2kzIgcXKafN7vWRASOIYkVGh2ZW54LQMFK2u0ZV5Y130_assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP362376.RA5S2kzIgcXKafN7vWRASOIYkVGh2ZW54LQMFK2u0ZV5Y130_provenance.
• NP775057.RAMYKwUkhbjTwJIgSaaE7qZ4J7LHUkS67uSSqvXx0T_ug130_assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP775057.RAMYKwUkhbjTwJIgSaaE7qZ4J7LHUkS67uSSqvXx0T_ug130_provenance.
• NP774847.RA_OwH_lRHNeMff7fvqkHtACw5wD-7_fK8wXWTBuwuk40130_assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP774847.RA_OwH_lRHNeMff7fvqkHtACw5wD-7_fK8wXWTBuwuk40130_provenance.
• NP847909.RAHdJpi5YqHwztjB7JQhujOKtj2Czpq72sE5dlfV_-6ds130_assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP847909.RAHdJpi5YqHwztjB7JQhujOKtj2Czpq72sE5dlfV_-6ds130_provenance.
• NP847914.RAEB3Cr7mcLDiPAu976tkhv_sOV4X4sJZlXAi553nrpmc130_assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP847914.RAEB3Cr7mcLDiPAu976tkhv_sOV4X4sJZlXAi553nrpmc130_provenance.
• NP847915.RAETtU1UOtRUKMWfhMj3wgNDG9g5MgfhBQCtPA-RehreU130_assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP847915.RAETtU1UOtRUKMWfhMj3wgNDG9g5MgfhBQCtPA-RehreU130_provenance.
• NP799358.RA0MzAs6B20uUTe9UFHzr-xXZq19FjGKgZ4_jizVBcm7U130_assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP799358.RA0MzAs6B20uUTe9UFHzr-xXZq19FjGKgZ4_jizVBcm7U130_provenance.
• NP847907.RAz6yzBh-8u-9CaG_qxDeLBWPlFIjnTVNO0PWo-i_WqRw130_assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP847907.RAz6yzBh-8u-9CaG_qxDeLBWPlFIjnTVNO0PWo-i_WqRw130_provenance.
• NP847912.RAzm3LwtSLDH4auloqfkB92hPdhelHQXniTCRLEz58dMc130_assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP847912.RAzm3LwtSLDH4auloqfkB92hPdhelHQXniTCRLEz58dMc130_provenance.
• NP847919.RA1ERajTKX_n89HHkdJf_NDzHr_oNAvHMSXW7P_BKLMVM130_assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP847919.RA1ERajTKX_n89HHkdJf_NDzHr_oNAvHMSXW7P_BKLMVM130_provenance.
• NP847921.RA6uC1rcpx5dAf0sv4yXllG10InipylRy5xVyrxsiH0fo130_assertion description "[We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP847921.RA6uC1rcpx5dAf0sv4yXllG10InipylRy5xVyrxsiH0fo130_provenance.